About Pyrotech
Pyrotech is a Healthcare company based in Beijing (China) founded in 2020 by TJ Deng and Feng Shao. Therapeutics for inflammatory and oncology conditions are manufactured and developed. It operates on a HealthTech model. Pyrotech has raised $96.92 million across 2 funding rounds from investors including China Taiping Insurance Group, Frees Fund and Lilly Asia Ventures. Its chief executive, as recorded, is TJ Deng. Pyrotech offers products and services including Biotechnology Solutions. Its focus areas include Biotechnology and Immunotherapy. Its legal entity is Pyrotech (Beijing) Biotechnology Co., Ltd.
Company details
Innovative biotechnology solutions are developed by Pyrotech to modulate innate immunity for treating human diseases. Focus is placed on the healthcare sector, specifically in immunotherapy. Research and development efforts are directed towards creating impactful therapies. Operations are based in China with facilities in Beijing and Shanghai.
- Headquarters Beijing, China
- Founders TJ Deng, Feng Shao
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website pyrotech.com
- Social LinkedIn
- Legal Name Pyrotech (Beijing) Biotechnology Co., Ltd.
- Total Equity Funding$96.92M (USD)
in 2 rounds
- InvestorsChina Taiping Insurance Group
& 8 more
Products & Services of Pyrotech
Pyrotech offers a comprehensive portfolio of products and services, including Biotechnology Solutions.
Solutions for modulating innate immunity are being developed.
Funding Insights of Pyrotech
Pyrotech has successfully raised a total of $96.92M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $96.92M
- Total Rounds 2
- First Round $96.92M
(Jul 2023)
- Investors Count 9
All 2 funding rounds of Pyrotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | Series A | – | – | ||
| Jul 2023 | $96.92M | Series A | – | SDIC Venture Capital Management |
9 investors in total: 9 institutional.
Investors in Pyrotech
Pyrotech has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include China Taiping Insurance Group, Frees Fund and Lilly Asia Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech focused VC firm investing in early stage companies in the US & China | freesvc.com | Beijing, China | ||
Venture capital investments are managed for innovative company growth. | sdicvc.com | Beijing, China | ||
| c-vc.com.cn | ||||
| tsinghua-vc.com | ||||
| chinalifeinvest.com | ||||
| lillyasiaventures.com | ||||
Diversified insurance and financial services are provided globally. | 1929 | cntaiping.com | Hong Kong, China | |
Investor details for Pyrotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Pyrotech
2 people are tracked at Pyrotech (2 in leadership).
| Name | Role | Group |
|---|---|---|
TJ Deng | Co-Founder & CEO | Leadership |
Feng Shao | Co-Founder | Leadership |
Complete people profiles for Pyrotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Pyrotech
3 dated milestones of Pyrotech across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Pyrotech is founded.
- Funding First funding round of $96.9M.
- Funding Latest funding round, Series A,.
Web traffic of Pyrotech
The website of Pyrotech (pyrotech.com) receives about 1.6K visits a month.
- Monthly visits1.6K
▼ 3.6% vs previous month
Websites whose visitors overlap most with Pyrotech. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
galaxy-fireworks.co.uk | galaxy-fireworks.co.uk | 100% | #3,491,366 | – | |
celfire.com | celfire.com | 100% | #5,237,085 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Pyrotech
Complete news archive for Pyrotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pyrotech
Pyrotech was founded in 2020 and raised its 1st funding round 3 years after it was founded.
Pyrotech is headquartered in Beijing, China.
TJ Deng is the CEO of Pyrotech, as recorded in our data. They have also founded this company.
Pyrotech is a funded company, having raised a total of $96.92M across 2 funding rounds to date. The company's 1st funding round was a Series A of $96.92M, raised on Jul 2023.
Innovative biotechnology solutions are developed by Pyrotech to modulate innate immunity for treating human diseases. Focus is placed on the healthcare sector, specifically in immunotherapy. Research and development efforts are directed towards creating impactful therapies. Operations are based in China with facilities in Beijing and Shanghai.
Pyrotech offers Biotechnology Solutions.
Pyrotech has 9 investors. Key investors include China Taiping Insurance Group, Frees Fund, Lilly Asia Ventures, SDIC Venture Capital, and China Venture Capital.
Pyrotech operates through Pyrotech (Beijing) Biotechnology Co., Ltd..